Peptides corresponding to the BH3 domains of Bax (BaxBH3) or Bcl-2 (Bcl2BH3) are potent inducers of apoptosis when fused to the Atennapedia plasma membrane translocation domain (Ant). BaxBH3Ant and Bcl2BH3Ant caused a mitochondrial membrane permeabilization (MMP) and apoptosis, via a mechanism that was not inhibited by overexpressed Bcl-2 or Bcl-X L , yet partially inhibited by cyclosporin A (CsA), an inhibitor of the mitochondrial permeability transition pore. When added to isolated mitochondria, BaxBH3 and Bcl2BH3 induced MMP, which was inhibited by CsA. However, Bcl-2 or Bcl-X L failed to inhibit MMP induced by BaxBH3 and Bc2BH3 in vitro, while they eciently suppressed the induction of MMP by the Vpr protein (from human immunode®ciency virus-1), a ligand of the adenine nucleotide translocator (ANT). BaxBH3 but not Bcl2BH3 was found to interact with ANT, and only BaxBH3 (not Bcl2BH3) permeabilized ANT proteoliposomes and induced ANT to form non-speci®c channels in electrophysiological experiments. In contrast, both BaxBH3 and Bcl2BH3 were able to stimulate channel formation by recombinant Bax protein. Thus, BaxBH3 might induce MMP via an action on at least two targets, ANT and Bax-like proteins. In contrast, Bcl2BH3 would elicit MMP in an ANT-independent fashion. In puri®ed mitochondria, two ligands of ANT, bongkrekic acid and the protein vMIA from cytomegalovirus, failed to prevent MMP induced by BaxBH3 or Bcl2BH3. In conclusion, BaxBH3 and Bcl2BH3 induce MMP and apoptosis through a mechanism which overcomes cytoprotection by Bcl-2 and Bcl-X L .
Introduction
Enhanced resistance to apoptosis may determine the survival of mutated cells during the initial stages of cancerogenesis. Accordingly, transgene-enforced overexpression of anti-apoptotic proteins such as Bcl-2 or Bcl-X L can facilitate the development of neoplasia (Meijerink et al., 1998; Pena et al., 1998; Shibata et al., 1999; Strasser et al., 1990) . More importantly, the acquisition of chemotherapy resistance may be determined, at least in part, by an increased resistance to apoptosis induction. As a result, approximately one half of human cancers have been reported to overexpress anti-apoptotic members of the Bcl-2 family or, conversely, to be de®cient in pro-apoptotic proteins from the Bcl-2 family, and this altered balance in the ratio between anti-and pro-apoptotic molecules can be correlated with prognosis (Ionov et al., 2000; Kitada et al., 1998) .
During recent years, it has become clear that mitochondrial membranes constitute the principal battleground of apoptosis regulation by Bcl-2-like proteins (Gross et al., 1999; Kroemer, 1997; Kroemer and Reed, 2000; Van der Heiden et al., 1999) . Antiapoptotic Bcl-2 proteins (Bcl-2, Bcl-X L , etc.), which are constitutively inserted into the outer mitochondrial membrane prevent the apoptosis-associated mitochondrial membrane permeabilization (MMP) (Kluck et al., 1997; Susin et al., 1996; Yang et al., 1997) . Proapoptotic members of the Bcl-2 family are either associated with mitochondria (e.g. Bak) or translocate from a non-mitochondrial localization to mitochondria (e.g. Bax, Bid, Bim etc.), followed by membrane insertion and oligomerization within mitochondrial membranes, thereby inducing MMP (JuÈ rgensmeier et al., 1998; Marzo et al., 1998a; Narita et al., 1998) . It appears that pro-apoptotic proteins structurally resembling to Bax and Bak (which share three Bcl-2 homology {BH} regions, BH1, BH2, BH3 with Bcl-2) are directly responsible for MMP , while so-called BH3-only proteins (Bid, Bim etc.) act in an indirect fashion, via interactions with other proteins from the Bcl-2 family, either by favoring their pro-apoptotic (pro-MMP) function or by neutralizing their anti-apoptotic (anti-MMP) properties (Adams and Cory, 2001; Cheng et al., 2001; Zong et al., 2001) . Although it is clearly established which Bcl-2-family member facilitates or inhibits MMP, the exact molecular mechanisms underlying such an MMPmodulatory function are the subject of an ongoing controversy. According to some authors, interactions among the Bcl-2 family suce to explain their function and Bax as well as Bak would form large, non-speci®c pores without the concourse of additional proteins (Martinou and Green, 2001) . In contrast, some data suggest that Bcl-2-like proteins modulate MMP through an interaction with sessile proteins clustered in the contract site of the outer and the inner mitochondrial membranes. Thus, interactions between Bcl-2 or Bax and the voltage-dependent anion channel (VDAC) (Shimizu et al., 1999) or the adenine nucleotide translocator (ANT) (Marzo et al., 1998a) have been detected, and channel formation by VDAC or ANT Zamzami and Kroemer, 2001 ) can reportedly be regulated by Bcl-2 and Bax. Interestingly, it appears that Bcl-2 and Bcl-X L can be converted into proapoptotic proteins through the action of proteases (caspases or calpains) that remove the N-terminal BH4 domain, which is constitutively lacking among the proapoptotic members of the family (Cheng et al., 1997; Nakagwa and Yuan, 2000) . This suggests that all Bcl-2-like proteins share a common structural feature, presumably the BH3 domain, which may exert a (latent) pro-apoptotic function.
The identi®cation of chemotherapeutic compounds which would neutralize Bcl-2 or Bcl-X L has been based on the idea that these proteins would possess a receptor-like structure, composed of the BH1, BH2, and BH3 domains, which would allow the docking of pro-apoptotic BH3 domains (Degterev et al., 2001; Sattler et al., 1997; Tzung et al., 2001; Wang et al., 2000; Zheng, 2001 ). Thus, BH3-peptides or peptidomimetics binding to the BH3 peptide-binding pocket of Bcl-X L or Bcl-2 have been shown to exert a proapoptotic function in several experimental systems (Cosulich et al., 1997; Degterev et al., 2001; Holinger et al., 1999; Tzung et al., 2001; Wang et al., 2000; Zheng, 2001) . Nonetheless, the mode of action of such pro-apoptotic BH3-peptides or peptidomimetics has been controversial. BH3-only peptides have been reported to induce apoptosis without MMP (Holinger et al., 1999) , to exclusively aect the outer mitochondrial membrane (Polster et al., 2001) or to simultaneously aect both the inner and the outer membranes . MMP induction by such compounds were reported to be unaected (Polster et al., 2001) or to be blocked by cyclosporin A. Similarly, MMP induction has been found to be inhibited (Polster et al., 2001) or not by Bcl-2 (Schimmer et al., 2001) .
Based on these premises, we re-examined the mechanisms of cell death induction by two BH3-peptides (derived from Bax and Bcl-2). We applied either native BH3 peptides or BH3 peptides fused to the Antennapedia plasma membrane translocation domain to intact cells, isolated mitochondria, or puri®ed mitochondrial proteins inserted into arti®cial membranes. Our results reveal that BH3 peptides can induce MMP and apoptosis in a fashion that is not modulated by Bcl-2 or Bcl-X L . In addition, we reveal that such peptides can act on dierent mitochondrial proteins (ANT or Bax), depending on their primary structure.
Results
Cell-permeable BH3 peptides overcome the apoptosisinhibitory effects of Bcl-2 and Bcl-X L Synthetic peptides corresponding to the BH3 domains from Bax (BaxBH3) or Bcl-2 (Bcl2BH3) fail to induce apoptosis when added to dierent cell lines (not shown), presumably because they fail to enter the cell. When fused to the Antennapedia (Ant) plasma membrane translocation domain (Derossi et al., 1994) , (Figure 2 ), BaxBH3Ant tended to be a more potent apoptosis inducer than Bcl2BH3Ant, although the dierences between both agents were more pronounced in HeLa cells than in lymphoma cells. Overexpression of Bcl-2 or Bcl-X L failed to prevent the signs of apoptosis induced by BaxBH3Ant or Bcl2BH3Ant, at various levels (DC m , viability, chromatin condensation), in all three cell lines that we tested (Figures 1 and 2) . In HeLa cells, overexpression of Bcl-2 or Bcl-X L even enhanced the proapoptotic eect of Bcl2BH3 but not that of BaxBH3 ( Figure 2b ). As an internal control of their ecacy, however, Bcl-2 and Bcl-X L potently inhibited apoptosis induction by the kinase inhibitor staurosporin, in all three cell lines (Figures 1b and 2a and data not shown for Jurkat cells). In conclusion, BaxBH3Ant and Bcl2BH3Ant peptides can potently induce apoptosis while overriding the cytoprotective eects of Bcl-2 and Bcl-X L .
Cell-permeable BH3 peptides induce MMP As shown above, BaxBH3Ant and Bcl2BH3Ant induce a loss of the DC m (Figure 3a ) . This eect was partially but reproducibly (®ve experiments) inhibited by cyclosporin A (CsA), an inhibitor of the mitochondrial permeability transition pore complex (Crompton, 1999) . In addition, we observed that BaxBH3Ant and Bcl2BH3Ant induced the translocation of cytochrome c (Cyt c) from the mitochondrial intermembrane space to the cytosol, as determined by immuno¯uorescence staining (Figure 3b ). Of note, upon addition of BaxBH3Ant or Bcl2BH3Ant to HeLa cells, the subcellular distribution of mitochondria changed. In untreated control cells, mitochondria created a preponderantly ®lamentous network, whereas BaxBH3Ant-or Bcl2BH3Ant-treated cells exhibited a dotshaped distribution of mitochondria. This re-organization, suggestive of mitochondrial ®ssion and/or swelling, was readily detected by staining cells with antibodies speci®c for the sessile mitochondrial antigen Cyt c oxidase (COX) and preceded the release of cytochrome c as well as the signs of advanced apoptosis such as chromatin condensation (Figure 3) . 
BH3 peptides induce MMP in isolated mitochondria
When added to puri®ed mouse liver mitochondria, both BaxBH3 and Bcl2BH3 provoked a rapid increase in mitochondrial volume (Figure 4a ). No such eect was observed when a scrambled control peptide identical in the aminoacid composition with (but dierent in the primary structure from) BaxBH3 was added to mitochondria (Figure 4a ). Concomitantly, BaxBH3 and Bcl2BH3 provoked the dissipation of the DC m (Figure 4b ). Both mitochondrial swelling and DC m loss were fully prevented by prior addition of CsA (Figure 4a,b) , an observation that suggests the involvement of the permeability transition pore complex in BaxBH3/Bcl2BH3-induced MMP. In contrast with one previous report , antimycin A (a blocker of the respiratory chain complex III) or oligomycin (an inhibitor of the F 1 F 0 ATPase) failed to prevent the BaxBH3/Bcl2BH3-induced DC m loss and rather tended to accelerate MMP induced by BaxBH3/ Bcl2BH3 (Figure 4b ). Exposure of mitochondria to BaxBH3 or Bcl2BH3 resulted in the release of Cyt c and AIF into the supernatant. Again, this eect was completely prevented by CsA, but not by antimycin A or oligomycin (Figure 4c ). In conclusion, BaxBH3 and Bcl2BH3 both can directly permeabilize mitochondrial membranes through a mechanism that is CsAsensitive.
BH3 peptides overcome the mitochondrio-protective effects of Bcl-2 and Bcl-X L As mentioned above, in intact cells, Bcl-2 or Bcl-X L fail to prevent MMP induced by BaxBH3Ant or Bcl2BH3Ant. This failure of Bcl-2 and Bcl-X L to protect mitochondria could be reproduced in a cellfree system. Puri®ed mitochondria from vector-only control cells or cells overexpressing Bcl-2 or Bcl-X L were exposed to BaxBH3 or Bcl2BH3 peptides. Neither Bcl-2 nor Bcl-X L (which are present in mitochondrial membranes, not shown) aected the release of Cyt c or AIF induced by BaxBH3 or Bcl2BH3 ( Figure 5 ). In a series of control experiments, however, Bcl-2 and Bcl-X L were found to protect isolated mitochondria against MMP induction by the human immunode®ciency virus-derived peptide Vpr52-96, in accord with previous reports ). In conclusion, it appears that BH3 peptides can overcome the mitochondrio-protective eects of Bcl-2 and Bcl-X L via a direct eect on mitochondria.
BaxBH3 but not Bcl2BH3 elicit pore formation by ANT
We have observed in the past that Bax, Bcl-2 and Vpr can interact with ANT Jacotot et al., 2000 Jacotot et al., , 2001 Marzo et al., 1998b) . To test whether ANT is actually the mitochondrial receptor of BH3 peptides, puri®ed mitochondria were incubated with biotinylated BaxBH3 or Bcl2BH3 (which are as ecient as non-modi®ed BaxBH3 or Bcl2BH3 in inducing mitochondrial swelling, not shown), followed by puri®cation of biotin-binding proteins on avidin agarose. This led to the recovery of ANT (but not VDAC) when biotinylated BaxBH3 was used as a bait (Figure 6 ). In strict contrast, neither ANT nor VDAC appeared to interact with Bcl2BH3 ( Figure 6 ). Next, we determined the capacity of BH3 peptides to permeabilize ANT proteoliposomes. BaxBH3 did cause the dose-dependent permeabilization of ANT proteoliposomes ( Figure 7a ). As a proof of speci®city, no permeabilization was observed when BaxBH3 was added to plain liposomes (Figure 7a ), and permeabilization of ANT proteoliposomes was counteracted by the physiological ANT ligand ATP (Figure 7c ). However, Bcl2BH3 had no or little eect on ANT proteoliposomes (Figure 7b ). Altogether, these data suggest that ANT is not the (sole) mitochondrial target of BH3 peptides. 
Both BaxBH3 and Bcl2BH3 elicit channel formation by Bax
In accord with the binding assays and the proteoliposome experiments, BaxBH3 caused ANT to form nonspeci®c, non-selective ion channels with a mean conductance of approximately 480 pS (Figure 8) , which is larger than the conductance obtained by combining the entire Bax protein and ANT 80 pS and not shown). BaxBH3 alone had no eects on plain membranes, and Bcl2BH3 had no eect at all (Figure 8 ). Some BH3-only proteins have been shown to act on Bax and to favor Baxmediated pore formation Zong et al., 2001) . Therefore, we determine whether BH3 peptides can change the electrophysiological properties of Bax. Both BaxBH3 and Bcl2BH3 were found to elicit channel formation by recombinant Bax protein inserted into a lipid bilayer, with conductances of 160 pS (for Bcl2BH3) and 500 ± 1000 pS (for BaxBH3), respectively, yet had no eects on plain membranes (Figure 8) . These results provide a tentative explanation how Bcl2BH3 can induce MMP.
BaxBH3 and Bcl2BH3-induced MMP is not inhibited by ANT ligands
The viral mitochondrial inhibitor of apoptosis (vMIA) encoded by cytomegalovirus speci®cally interacts with ANT (Goldmacher et al., 1999; Vieira et al., 2001 ) and this property is thought to account for its MMPstabilizing activity. Whereas BJAB cells (Figure 9 ) and HeLa cells (not shown) overexpressing vMIA are protected against apoptosis induced by staurosporin, no such inhibitory eect of vMIA was observed when cells were killed by BaxBH3Ant or Bcl2BH3Ant (Figure 9 ). Similar results were obtained when the eects of BaxBH3 and Bcl2BH3 on isolated mitochondria were evaluated. Bongkrekic acid (BA), an apoptosis-inhibitory ANT ligand, failed to prevent mitochondrial potential collapse induced by BaxBH3 or Bcl2BH3 (Figure 10a ), as well as Cyt c and AIF release (Figure 10b ). In addition, mitochondria puri®ed from vMIA-overexpressing cells readily released Cyt c and AIF when exposed to BaxBH3 or Bcl2BH3 (Figure 10c ). In conclusion, it appears that apoptosisinhibitory ANT ligands such as BA or vMIA fail to prevent MMP and apoptosis induced by BaxBH3 or Bcl2BH3.
Concluding remarks
Here, we report that peptides corresponding to the BH3 domains of Bax and Bcl-2 can induce MMP and apoptosis through a pathway that is not inhibited by overexpression of Bcl-2 and Bcl-X L . In contrast to fulllength Bax (Gross et al., 1999; Vander Heiden and Thompson, 1999) and to Vpr ) (which would be antagonized by Bcl-2 or Bcl-X L ), the BH3 peptide derived from Bax (BaxBH3) induces apoptosis via a novel mechanism not relying on ANT. Although BaxBH3 was found to interact with ANT and to permeabilize ANT proteoliposomes (and to induce channel formation by ANT), anti-apoptotic ANT ligands such as BA and vMIA failed to antagonize BaxBH3-induced MMP and apoptosis. Bcl2BH3, which does not interact with ANT, neither physically nor functionally, was nearly as potent as BaxBH3 in inducing MMP and in killing cells, and again its eects were not counteracted by BA or vMIA. Both BaxBH3 and Bcl2BH3, however, can stimulate the channel function of recombinant Bax inserted into lipid bilayers, suggesting that such peptides can trigger MMP through a direct action on pro-apoptotic members of the Bcl-2 family locally present in mitochondrial membranes.
We have found in the past that the MMP-inhibitory spectrum of action of Bcl-2 and BA was similar, in the Figure 6 Interaction between BaxBH3, but not Bcl2BH3, with ANT. (a) Isolated mouse liver mitochondria or (b) puri®ed HeLa mitochondria were treated with 5 or 10 mM biotinylated BH3 peptides for 20 min at room temperature. After mitochondrial lysis, avidin beads were added for a 2 h incubation at 48C, followed by washing the beads six times before solubilization of the attached proteins from the beads with Laemmli buer and immunodetection of ANT and VDAC. This experiment has been repeated three times, with similar results sense that the same inducers (high Ca 2+ doses, caspases, diamide, PK11195) which overcame the MMP inhibitory eect of BA did also overcome the anti-MMP aect of Bcl-2 (Costantini et al., 2000a,b; Hirsch et al., 1998; Marzo et al., 1998b) . The data reported here extend this correlation and suggest that agents which induce MMP in a fashion that bypasses ANT (or the regulation of ANT by vMIA and BA) will also bypass the regulatory eects of Bcl-2-like antiapoptotic proteins. Of note, we found that MMP induced by BaxBH3 or Bcl2BH3 was inhibited by CsA. This eect was complete, when evaluated on isolated mitochondria (time scale: minutes), and partial, when evaluated on intact cells (time scale: hours), in line with the reported transient MMP-inhibitory eect of CsA (Bernardi et al., 2001) . CsA reportedly acts on the matrix protein cyclophilin D, and its MMP-protective action may be attributed to indirect conformational eects on a VDAC-ANT-cyclophilin D complex (Crompton et al., 1998; Wood®eld et al., 1998) . It remains elusive, however, through which exact molecular mechanism CsA may prevent MMP induced by BaxBH3 or Bcl2BH3. Moreover, it is not clear through which mechanism BaxBH3 and Bcl2BH3 can overcome cytoprotection by Bcl-2, Bcl-X L , and vMIA. As a possibility, these proteins may act on sessile mitochondrial proteins, including dierent members of the Bcl-2 family (Bax, Bcl-2 etc.), thereby facilitating the generation of non-speci®c channels (as shown for the interaction with Bax). Apparently, the BaxBH3 and Bcl2BH3 peptides have slightly dierent actions on such Bcl-2 family members. For instance, BaxBH3 elicits Bax channels with a higher conductance than does Bcl2BH3. In addition, it appears that, to some extent, overexpression of Bcl-2 and Bcl-X L enhanced the pro-apoptotic eect of Bcl2BH3 but not that of BaxBH3. Whether this is due to direct interactions (and channel formation) between Bcl-2 or BclXL and Bcl2BH3 remains to be determined.
Irrespective of the detailed mechanisms through which BaxBH3 and Bcl2BH3 induce MMP and apoptosis, our ®ndings underline that BaxBH3 and Bcl2BH3 kill in a fashion that is not in¯uenced by the expression level of Bcl-2 or Bcl-X L . This suggests that, in addition to pharmacological strategies aiming at down-regulating Bcl-2 expression levels (e.g. by antisense oligonucleotides) (Banerjee, 2001) , BH3 peptidomimetics may be developed which induce apoptosis in Figure 10 Failure of the ANT ligands BA and vMIA to prevent DCm loss or Cyt c and AIF release. (a, b) Isolated mouse liver mitochondria were exposed to BA (5 min), followed by addition of Atractyloside (Atre) (positive control for the BA eect) or BH3. In a recordings of rhodamine quenching are shown. In b the release of AIF or Cyt c into the supernatants was monitorated by immunoblots. (c) Puri®ed mitochondria, from control BJAB cells or cells overexpressing vMIA, were treated with 5 or 10 mM BaxBH3 or Bcl2BH3 for 20 min at room temperature, followed by AIF and Cyt c immunodetection in the supernatants. Results are representative of three independent determinations spite of the overexpression of anti-apoptotic Bcl-2-like proteins.
Materials and methods

Synthetic Peptides
Peptides were synthetized by Syntem (NõÃ mes, France), puri®ed by the chromatographic technic HPLC, and controled by mass spectroscopy. The synthetic peptides present the following sequences: BaxBH3 57-NH2-KKLSECLKRIGDELDS-COOH-72 ; Bcl2BH3 91-NH2-PVVHLTLRQAGDDFSR-COOH-106; BaxBH3Ant NH2-KCRKKKRRQRRRKKLSECLKRIGDELDS ± COOH; Bcl2BH3Ant NH2-KCRKKKRRQRRRPVVHLTLRQAGD-DFSR ± COOH; BiotBH3Bax biot-KKLSECLKRIGDEL-DS-COOH; BiotBH3Bcl-2 biot-PVVHLTLRQAGDDFSR-COOH; scrambled BaxBH3 NH2-LDILSGKRDEKLSKEC-COOH; scrambled BaxBH3Ant NH2-KCRKKKRRQRRR-LDILSGKRDEKLSKEC-COOH and Vpr 52-96 (Cornille et al., 1999; SchuÈ ler et al., 1999) .
Cell lines and apoptosis induction
Jurkat cells transfected with the human Bcl-2 gene (Aillet et al., 1998) ; and HeLa or BJAB cells transfected with the cytomegalovirus UL37 exon 1 gene coding for vMIA and with the human Bcl-2 and Bcl-X L gene (kindly provided by Dr V Goldmacher) (Goldmacher et al., 1999) , as well as control cells transfected with the pcDNA3.1 vector containing the neomycin resistance gene (Neo), were cultured in RPMI-1640 (BJAB and Jurkat) or DMEM (HeLa) medium supplemented with 2 mM glutamine, 10% FCS, 1 mM pyruvate, 10 mM HEPES and 100 U/ml pencillin/streptomycin at 378C under 5% CO 2 . 1 ± 5610 5 cell/ml were treated with various doses of BH3 domain of Bax and Bcl-2 fused to the Antennapedia (Ant) domain, which allows for cell entry, for 30 min in culture medium without FCS, then supplemented with FCS for the rest of the incubation time: overnight for HeLa cells and 4 h for BJAB cells at 378C. For cell death inhibition, cyclosporin A was tested on BJAB cells, which were treated 15 min with CsA at 2 mM before adding BH3 peptides.
Assessment of apoptosis-associated parameters
The following¯uorochromes were employed to assess apoptosis-associated changes by cyto¯uorometry on a FACS Vantage (Becton Dickinson), while gating the forward and the side scatters on viable cells: 3,3' dihexyloxacarbocyanine iodide (DiOC 6 (3), 20 nM) for DC m quanti®cation, propidium iodide (PI, 1 mg/ml) for the determination of cell viability. Alternatively, cells cultured on a cover slip were stained with 5,5',6,6'e-tetrachloro-1,1', 3,3'e-tetraethylbenzimidazolylcarbocyanine iodide (JC-1, 3 mM, Molecular Probes) and Hoechst 33342 (2 mM, Sigma), followed by¯uorescence microscopic assessment of apoptotic parameters, as described Ferri et al., 2000) . Cells were ®xed on paraformaldehyde (4% w : v) and picric acid (0.19% v : v) for immuno¯uorescence assays. Cells were stained for the detection of cytochrome c (mAb 6H2.B4 from Pharmingen, detected by a goat anti-mouse IgG conjugated with Alexa ) were washed once in PBS and incubated 5 min in ice cold hypotonic buer (0.15 mM MgCl 2 , 10 mM KCl and Tris HCl, pH 7.6, supplemented with the protease inhibitor cocktail, Roche). An equal volume of 26 mitochondria homogenization buer (600 mM saccharose, 5 mM TES, 200 mM EGTA, pH 7.2) was added and the samples were homogenized with a potter Thomas 50 times at 48C. Cell lysates were centrifugated twice (5 min, 900 g, 48C) to remove nuclei and unbroken cells and the supernatants were centrifugated again (10 min, 10 000 g, 48C) to recover the mitochondrial pellet. Mitochondria were treated with various doses of BH3 domain of Bax and Bcl-2 and the control peptide Vpr52-96 at 4 mM for 20 min at room temperature, followed by centrifugation (10 000 g, 10 min, 48C). Proteins contained in the supernatants were then concentrated in 90% acetone (48C, 18 h; centrifugation at 20 000 g, 20 min, 48C) and the precipitate was subjected to 12% SDS ± PAGE, Western blot, and immunodetection with mouse anti-cytochrome c or with a rabbit antiserum generated against aminoacids 151 to 200 of AIF (Susin et al., 1999) . Cytochrome c and AIF were detected on the same immunoblot.
Isolation of mouse liver mitochondria and measurement of pemeobility transition (PT) opening
Mitochondria were puri®ed from Balb/c mouse livers on a Percoll 1 gradient . One mg/ml of mitochondrial protein were resuspended in 0.2 M sucrose, 10 mM Tris-MOPS, pH 7.4, 5 mM succinate-Tris, 1 mM Pi, 2 mM rotenone and 10 mM EGTA-Tris (swelling buer). PT pore opening was monitored as the change of 908 light scattering at 560 nm using a Hitachi F-4500¯uorescence spectrophotometer. In addition, DCm was measured by rhodamine 123 at 5 mM (excitation at 505 nm and emission at 535 nm), the increase in emission corresponds to the DC m decrease by the¯uorochrome dequenching eect (Narita et al., 1998) . After swelling and DCm measurements, the samples were centrifuged at 10 000 g, 10 min and at 48C, and proteins from the supernatant were concentrated in acetone overnight at 48C, for Western blot immunodetection with mouse anti-cytochrome c and with a rabbit antiserum generated against aminoacids 151 to 200 of AIF .
Purification of ANT and its reconstitution into liposomes
Rat heart mitochondria were isolated for ANT puri®cation. After mechanical shearing, mitochondria were suspended in 220 mM mannitol, 70 mM sucrose, 10 mM HEPES, 200 mM EDTA, 100 mM DTT, 0.5 mg/ml subtilisin (Sigma), pH 7.4, kept 8 min on ice and sedimented twice by dierential centrifugations (5 min, 500 g and 10 min, 10 000 g). Mitochondrial proteins were solubilized by 6% [v : v] Triton X-100 (Boehringer Mannheim) in 40 mM K 2 HPO 4 , 40 mM KCl, 2 mM EDTA, pH 6.0, for 6 min at RT and solubilized proteins were recovered by ultracentrifugation (30 min, 24 000 g, 48C). Then, the Triton X-100 extract was applied to columns ®lled with 1 g of hydroxyapatite (BioGel HTP, BioRad), eluted with the previous buer and diluted [v : v] with 20 mM MES (2-[N-morpholino]ethanesulfonic acid), 200 mM EDTA, 0.5% Triton X-100, pH 6.0. Subsequently, the sample was separated on a Hitrap SP column using a FPLC system (Pharmacia) and a linear NaCl gradient (0 ± 1 M) (Marzo et al., 1998a) . Puri®ed ANT was reconstituted in phosphatidylcholine/cardiolipin liposomes. For liposome preparation, 90 mg phosphatidylcholine and 2 mg cardiolipin were mixed in 1 ml choroform, and the solvent was evaporated under nitrogen. Dry lipids were resuspended in 1 ml liposomes buer (125 mM sucrose, 10 mM HEPES, pH 7.4) containing 0.3% n-octyl-b-D-pyranoside and mixed by continuous vortexing for 40 min at RT. ANT (0.1 mg/ml) was then mixed with liposomes [v : v] and incubated for 15 min at RT. ANT proteoliposomes were ®nally dialyzed overnight at 48C. Plain liposomes were produced for control tests .
Quantification of liposomal permeabilization
Plain liposomes and ANT proteoliposomes were sonicated in the presence of 4-umbelliferylphosphate (4-MUP, 1 mM, Sigma) and 10 mM KCl (50 W, 22 s, Branson soni®er 250) on ice and washed on Sephadex G-25 columns (PD-10, Pharmacia). Twenty-®ve ml-aliquots of liposomes were mixed [v : v] with various concentrations of BH3 peptides, incubated for 1 h at RT and diluted to 200 ml in liposomes buer. The speci®c inhibitor of ANT, ATP was added at 500 mM to the liposomes 15 min before BH3 peptides. After addition of 10 ml alkaline phosphatase (5 U/ml, Boehringer Mannheim) diluted in liposomes buer supplemented with 0.5 mM MgCl 2 , samples were incubated for 15 min at 378C and the enzymatic conversion of 4-MUP to 4-MU (4-methylumbelliferone) was stopped by addition of 50 ml stop buer (10 mM HEPES-NaOH, 200 mM EDTA, pH 10.0). Fluorescence was subsequently determined using a Perkin Elmer spectrouorimeter (excitation 365 nm, emission 450+5 nm). Atractyloside, an ANT speci®c pro-apoptotic permeability transition inducer, was used in each experiment as a standard to determine the 100% response (Costantini et al., 2000a) .
Co-precipitation between BH3 domain peptides and other proteins
Five hundred mg mouse liver mitochondria or HeLa cell mitochondria were treated with biotinylated BH3 domain peptides for 20 min at room temperature, followed by centrifugation at 10 000 g, 10 min at 48C to eliminate the supernatant. Pellets were lysed with PBS 0.5% Triton X-100 1 mM EDTA for 10 min at 48C. Fifty ml of pre-washed avidin beads were added for 2 h at 48C under gentle shacking incubation. The beads were washed six times (600 g, 5 min and 48C). Proteins attached to the beads were solubilized by Laemmli buer, separated under reducing conditions by SDS/PAGE, and subjected to immunoblots using the ECL (enhanced chemoluminescence) detection system (Amersham). The following primary antibodies were used: anti-human VDAC Ab-4 (Calbiochem) and anti-ANT rabbit antiserum raised against puri®ed rat heart ANT (Marzo et al., 1998a) . Secondary antibodies were HRP-labeled anti-mouse IgG (Jackons Labs) or anti-rabbit IgG (Southern Biotechnology).
Electrophysiological measurements
Virtually solvent-free planar lipid bilayers were formed by the method of Montal and Mueller (1972) by the apposition of two monolayers on 125 mm-diameter hole in thin Te¯on ®lm (10 mm) pre-treated with hexadecane/hexane (1: 40, v : v) . Measurement compartments were glass cells. Membrane currents under applied voltage were measured using a BLM 120 ampli®er (Biologic) and Ag/AgCl electrodes. The current¯uctuations were stored on a DRA200-DAT (Biologic) and were transferred to a computer where dierent measurements (current and histogram amplitude) were performed using software from ADInstruments. The lipid mixture PalmitoylOleoyPhosphatidylCholine/DiOleoylPhosphatidylEthanolamine (POPC/DOPE; 7:3; w:w) supplemented with 3% cardiolipin (Lipid Products) and dissolved in hexane (0.5%, p/v was used. The electrolyte solution was 0.1 M KCl, 10 mM N-2-hydroxyethylpiperazine-N'-2 ethanesulfonic acid (HEPES), 1 mM MgCl2 (pH 7.4) Jacotot et al., 2001) . The protein concentration was 1 nM for ANT, BH3Bcl2 and BH3Bax.
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